Consumer Full‑Body‑Scan Boom

Well‑capitalized startups are trying to make routine, full‑body diagnostic scanning a consumer commodity (hourly clinics, automated AI readouts) that promises early detection. Scaling these services into the U.S. will produce three concrete effects: large proprietary medical datasets, potential surges in low‑value follow‑ups (false‑positive cascades) that stress clinical care, and unsettled questions about who owns, audits and regulates diagnostic AI. — Widespread consumer body‑scanning could reshape health‑care costs, clinical workflows, privacy law, and where medical AI gets trained — forcing national policy choices on screening standards, data governance, and who pays for downstream care.